Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter W de Herder

Showing results (41-50 of 238) with videos related to

Pageof 24
Sort By:
Molecular and Cellular Endocrinology|May 5, 2010
Pituitary tumours: the sst/D2 receptors as molecular targetsLeo J Hofland, Richard A Feelders, Wouter W de Herder, et al.
Endocrine|May 2, 2003
Octreoscan radioreceptor imagingAart J van der Lely, Wouter W de Herder, Eric P Krenning, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 26, 2012
[Outpatient surgical treatment of primary hyperparathyroidism]Tessa M van Ginhoven, Wanda Geilvoet, Wouter W de Herder, et al.
Endocrine-Related Cancer|May 10, 2017
Effect of hormone secretory syndromes on neuroendocrine tumor prognosisWouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, et al.
Journal of Neuroendocrinology|June 8, 2023
Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN surveyJorge Hernando, Teodora Kolarova, Chris Verslype, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort StudyMerijn C F Mulders, Celine F Maas, Richard A Feelders, et al.
European Journal of Endocrinology|May 13, 2022
Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patientsJulie Refardt, Tessa Brabander, Noémie S Minczeles, et al.
Cancers|December 11, 2022
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsMorticia N Becx, Noémie S Minczeles, Tessa Brabander, et al.
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|December 16, 2021
Matching-adjusted indirect treatment comparison of [<sup>177</sup>Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [<sup>177</sup>Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumoursMohid S Khan, Elaine Stamp, Cormac Sammon, et al.
Clinical Endocrinology|September 14, 2012
The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET)George Kanakis, Kimberly Kamp, Konstantinos Tsiveriotis, et al.
Pageof 24

Showing results (41-50 of 238) with videos related to

Sort By:
Pageof 24
Molecular and Cellular Endocrinology|May 5, 2010
Pituitary tumours: the sst/D2 receptors as molecular targetsLeo J Hofland, Richard A Feelders, Wouter W de Herder, et al.
Endocrine|May 2, 2003
Octreoscan radioreceptor imagingAart J van der Lely, Wouter W de Herder, Eric P Krenning, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 26, 2012
[Outpatient surgical treatment of primary hyperparathyroidism]Tessa M van Ginhoven, Wanda Geilvoet, Wouter W de Herder, et al.
Endocrine-Related Cancer|May 10, 2017
Effect of hormone secretory syndromes on neuroendocrine tumor prognosisWouter T Zandee, Kimberly Kamp, Roxanne C van Adrichem, et al.
Journal of Neuroendocrinology|June 8, 2023
Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN surveyJorge Hernando, Teodora Kolarova, Chris Verslype, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 13, 2026
Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort StudyMerijn C F Mulders, Celine F Maas, Richard A Feelders, et al.
European Journal of Endocrinology|May 13, 2022
Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patientsJulie Refardt, Tessa Brabander, Noémie S Minczeles, et al.
Cancers|December 11, 2022
A Clinical Guide to Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Neuroendocrine Tumor PatientsMorticia N Becx, Noémie S Minczeles, Tessa Brabander, et al.
EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [Et Al.]|December 16, 2021
Matching-adjusted indirect treatment comparison of [<sup>177</sup>Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [<sup>177</sup>Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumoursMohid S Khan, Elaine Stamp, Cormac Sammon, et al.
Clinical Endocrinology|September 14, 2012
The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP-NET)George Kanakis, Kimberly Kamp, Konstantinos Tsiveriotis, et al.
Pageof 24